In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardiNor Leads The Charge As Norway Gets Behind Life Sciences

Executive Summary

Norwegian start-up CardiNor is developing a new cardiovascular biomarker, and is hopeful of attracting cash in a country where investor traditions are undergoing some changes. The financial pressures caused by falling oil prices have brought renewed attention to life science companies.

You may also be interested in...



Start-Up Quarterly Statistics, Q1 2016

Start-ups raised $1.8 billion in Q1 2016. Biopharma companies penned 33 alliances; 14 acquisitions were signed (11 in the biopharma industry).

Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch

The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.

Biosecurity Centre And ‘Test And Trace’ To Augment UK’s COVID-19 Test Momentum

The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel